Aspergillosis Treatment Market, By Drug Class, By Disease Type, By Geography

Description

Aspergillosis Treatment Market is estimated to be valued at USD 4.95 Bn in 2026 and is expected to reach USD 6.51 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 4.95 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.00%	2033 Value Projection:	USD 6.51 Bn

Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to aspergillus induced infection. Common aspergillus infections include invasive aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary Aspergilloma (CPA). Azoles are the only oral drug with anti-aspergillus activity and itraconazole and voriconazole are considered as first-line drugs for chronic pulmonary aspergillosis.

Market Dynamics

Key players operating in the market are focusing on development and approval of novel therapeutics for the treatment of chronic aspergillosis, which is expected to offer a lucrative opportunity to the market players to launch innovative products in the market for the treatment of aspergillosis. For instance, In October 2017, Mylan N.V. launched caspofungin acetate for injection, one of the first generic versions of the U.S. pharma giant Merck's & Co's Cancidas. It is indicated for invasive aspergillosis in patients who are refractory to or intolerant of other therapies. Furthermore, key companies in the market focusing on growth strategies such as FDA approvals which is expected to drive the growth of the market over forecast period. For instance, In January 2020, PULMATRiX, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to PUR1900 (Pulmazole). The company's inhaled itraconazole antifungal candidate is developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic aspergillosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chronic aspergillosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic aspergillosis treatment market

Aspergillosis Treatment Market Segmentation

By Drug Class (Revenue, USD Bn, 2021-2033)
- Corticosteroids
- Anti-fungal
By Disease Type (Revenue, USD Bn, 2021-2033)
- Invasive Aspergillosis
- Chronic Pulmonary Aspergillosis
- Allergic Bronchopulmonary Aspergillosis
- Allergic Aspergillus Sinusitis
- Aspergilloma
- Cutaneous Aspergillosis
Global Aspergillosis Treatment Market, By Region: (Revenue, USD Bn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Abbott Laboratories
- AstraZeneca plc
- Eli Lilly and Company
- GlaxoSmithKline
- Johnson & Johnson Services, Inc.
- Mylan Pharmaceuticals, Inc.
- Novartis AG
- Pfizer, Inc.
- Takeda Pharmaceutical Company Ltd.

Product Code: CMI4611

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Aspergillosis Treatment Market, By Drug Class, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Anti-fungal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. Global Aspergillosis Treatment Market, By Disease Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Chronic Pulmonary Aspergillosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Allergic Bronchopulmonary Aspergillosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Allergic Aspergillus Sinusitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Aspergilloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
Cutaneous Aspergillosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. Global Aspergillosis Treatment Market, By Region, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Abbott Laboratories
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AstraZeneca plc Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- GlaxoSmithKline
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Johnson & Johnson Services, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Mylan Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
  - Analyst Views

8. Section

References
Research Methodology
About Us